The study began field preparations on 20 April 2020 andrecruitment started immediately. Already, 62 medical institutions in 29countries have agreed to participate. Professor Villar stated: “This large study benefits from theUniversity having hosted, over the last 12 years, a network of researchersacross the world who have participated in the INTERGROWTH-21stProject. As a result, we have in place trained research staff and standardiseddata collection forms. All the work is done via an online data collectionsystem that provides information almost in real-time.” In the INTERCOVID study researchers will be recruiting womenwho are and are not exposed to Covid-19 at any stage of pregnancy, followingmothers and new-borns until hospital discharge post-delivery. Professor Aris Papageorghiou (NDWRH), who is jointly leadingthe research, said that the “truly remarkable” response from internationalcolleagues “means the study should have significant power to provide invaluableanswers, in a short time period, regarding the risks to pregnant women who areexposed to SARS-CoV-2.” Professor Stephen Kennedy (NDWRH), who is jointly leadingthe research, said that a failure to obtain this information “runs the risk ofpregnant women being denied priority access to a new vaccine or therapy, as hasoccurred so many times in the past.” It looks to collect invaluable baseline data as recommendedby the Pregnancy Research Ethics for Vaccines, Epidemics and New Technologies(PREVENT) Report, in order to inform risk-benefit analyses for future vaccinetrials in pregnant women by providing “potential risk relationships betweenvaccination and adverse events.” It is believed that pregnant women with Covid-19 are at asimilar risk to the general population, but there is currently limited dataavailable to provide accurate evidence for this claim. The information isneeded quickly in order to optimise the care available for women and their new-borns,reduce maternal anxiety, inform decision making about resource allocation, andguide the process toward social adaptation. INTERCOVID is a large, multi-national, prospective cohortstudy, coordinated by the INTERGROWTH-21st Team at the University ofOxford. Professor Jose Villar of the University’s Nuffield Department ofWomen’s & Reproductive Health (NDWRH), is leading the research. The study defines “exposed” cases as pregnant women with anyof the following: “laboratory-confirmed Covid-19; radiological pulmonaryfindings suggestive of Covid-19; maternal symptoms compatible with Covid-19;absence of symptoms, whilst in close interaction with a person(s) withconfirmed Covid-19.” Each “exposed” case is compared with two “non-exposed”pregnant women, considered as a representative of the pregnancy population ateach study site. On the 24th of April, researchers at the University of Oxford launched a global study to evaluate the effects of Covid-19 in pregnancy. The INTERCOVID study will be used to advise families, health care providers and policymakers with high-quality evidence regarding the effects of Covid-19 in maternal, fetal and neonatal outcomes. The team has been contacted for comment. Image by gdakaska from Pixabay.